274 related articles for article (PubMed ID: 11747598)
1. Helper plasmids for production of HIV-1-derived vectors.
Fuller M; Anson DS
Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
[TBL] [Abstract][Full Text] [Related]
2. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
4. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
Sparacio S; Pfeiffer T; Schaal H; Bosch V
Mol Ther; 2001 Apr; 3(4):602-12. PubMed ID: 11319923
[TBL] [Abstract][Full Text] [Related]
5. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.
Kotsopoulou E; Kim VN; Kingsman AJ; Kingsman SM; Mitrophanous KA
J Virol; 2000 May; 74(10):4839-52. PubMed ID: 10775623
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
7. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system.
Pandya S; Boris-Lawrie K; Leung NJ; Akkina R; Planelles V
Hum Gene Ther; 2001 May; 12(7):847-57. PubMed ID: 11339901
[TBL] [Abstract][Full Text] [Related]
8. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
9. Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems.
Matukonis M; Li M; Molina RP; Paszkiet B; Kaleko M; Luo T
Hum Gene Ther; 2002 Jul; 13(11):1293-303. PubMed ID: 12162812
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production.
Koldej R; Cmielewski P; Stocker A; Parsons DW; Anson DS
J Gene Med; 2005 Nov; 7(11):1390-9. PubMed ID: 16025547
[TBL] [Abstract][Full Text] [Related]
11. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
12. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.
Molina RP; Ye HQ; Brady J; Zhang J; Zimmerman H; Kaleko M; Luo T
Hum Gene Ther; 2004 Sep; 15(9):865-77. PubMed ID: 15353041
[TBL] [Abstract][Full Text] [Related]
13. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene.
Harrison GS; Long CJ; Curiel TJ; Maxwell F; Maxwell IH
Hum Gene Ther; 1992 Oct; 3(5):461-9. PubMed ID: 1329991
[TBL] [Abstract][Full Text] [Related]
15. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein.
Schwartz S; Felber BK; Pavlakis GN
J Virol; 1992 Jan; 66(1):150-9. PubMed ID: 1727477
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
17. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.
Curran MA; Kaiser SM; Achacoso PL; Nolan GP
Mol Ther; 2000 Jan; 1(1):31-8. PubMed ID: 10933909
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of intronic and exonic locations of the human immunodeficiency virus type 1 Rev-responsive element.
Campbell LH; Borg KT; Arrigo SJ
Virology; 1996 May; 219(2):423-31. PubMed ID: 8638408
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
20. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
Liem SE; Ramezani A; Li X; Joshi S
Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]